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The development of a fertility preservation decision aid to 
support teenage and adult women with cancer
Jones GL et al….and on behalf of the Cancer, Fertility and Me study group).
Fertility preservation and 
decision-making
Many women with a cancer diagnosis have to make time-pressured decisions 
regarding fertility preservation with specialist fertility services, whilst undergoing 
treatment of their cancer with oncology/haematology services.
Our recent narrative review exploring the factors which hindered women’s 
decisions about fertility preservation after a cancer diagnosis suggested that many 
women do not feel well supported in making these decisions. Lack of specialist 
fertility preservation information and the timing of this information were found to 
be key factors. [1] 
Similarly, a recent prospective, mixed-method study in Sheffield found that women 
with cancer wanted to receive specialist fertility information sooner, in the context 
of their cancer care, and in advance of seeing the fertility expert. They felt this 
would help them better prepare for the fertility decision and ensure they made the 
best decision for their future aspirations. [2]
Although there are many fertility preservation resources publically available for 
women with cancer, none have been developed for UK female cancer patients, and 
the two existing patient decision aids (ptDA’s) are exclusively for women with 
breast cancer. [3]
The ‘Cancer Fertility and Me’ project
The aim of the project is to develop a ptDA to meet this patient need and enable cancer and 
fertility services to support women’s fertility preservation decisions following a diagnosis of 
any cancer type. 
Our objectives are to:
1. Develop a ptDA for use by oncology/haematology teams to support teenage and adult 
women (16 years +) making fertility preservation choices.
2. Assess the face validity of the ptDA to teenage and adult women with cancer and 
oncology, haematology and fertility health care professionals.
3. Evaluate its acceptability (using both qualitative and quantitative methods) to:
a) women making fertility preservation decisions whilst planning their cancer treatment,
b) oncology, haematology and fertility health professionals supporting women’s oncology 
and fertility treatment choices.
Design
A prospective, observational study using mixed-methods will be carried out across 
3 stages, (table 1) to assess the ptDA’s acceptability to women and professionals in 
usual cancer care and fertility service settings. Figure 1 shows the recruitment 
process, timings of the data collection and outcome measures to be used.
Ethical Considerations
Ethics approval was granted on 5th April 2016 (Ref: 16/EM/0122) and Health 
Research Authority approval on 20th June 2016 (Ref: 194751). The protocol is also 
registered with clinicaltrials.gov (ID: NCT02753296).
Implications
• To the best of our knowledge, this research will develop the first, open access, evidence-based fertility preservation decision aid that is suitable for women of reproductive age 
(16 years +) and diagnosed with any cancer.
• The research will provide evidence of its acceptability and utility to women and healthcare professionals in usual practice across cancer and fertility care pathways.
• The research will provide evidence for the causal assumptions of its effectiveness and issues for implementation in usual care practice.
• This research will not provide evidence of its effectiveness on healthcare outcomes. However, our findings will provide the evidence to inform the study design for evaluating 
the effectiveness of this complex intervention on health outcomes in the future.
The ptDA
The ptDA uses guidance from the International Patient Decision Aid Standards collaboration 
[4] on balance of options, risk presentation, elicit values, use patient stories, enabling 
readability, and understanding illness.
The ptDA will structure information to encourage women to evaluate all decision options 
and their consequences in accordance with their values without bias, and to make a decision 
based on their trade-offs between these evaluations, i.e. to make a reasoned decision. 
The aim is for women to receive the ptDA from their cancer health care professionals as part 
of usual care on diagnosis of cancer and before referral to fertility services. 
The ptDA is being disseminated as both a leaflet and PDF on a website, and evaluated 
accordingly.
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